Glycominds is a pioneering leader in the development, production and marketing of advanced glycan-based predictive serological testing for autoimmune and cancer diseases.
The company's focus is on clinical practice applications which have been shown to significantly improve quality-of-treatment decisions for autoimmune patients and early detection of cancers. As the glycan specialist, Glycominds is leveraging its novel GlycoChip® technology, in continuously discovering and validating novel glycan markers, ensuring the ongoing development of a stream of other high-accuracy serological products. The company maintains headquarters at Lod, Israel, with U.S. branch offices at Redwood City, California, and clinical lab services in Luxemburg.

More about Glycominds